With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.

Hormone refractory prostate cancer, Novel therapeutics, PSA biomarker, Xenografts
dx.doi.org/10.1038/sj.bjc.6604822, hdl.handle.net/1765/27068
British Journal of Cancer
Erasmus MC: University Medical Center Rotterdam

van Weerden, W.M, Bangma, C.H, & de Wit, R. (2009). Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. British Journal of Cancer, 100(1), 13–18. doi:10.1038/sj.bjc.6604822